Stock Price Quote

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE450.256.85 (+1.54 %)
PREV CLOSE ( ) 443.40
OPEN PRICE ( ) 445.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 78955
TODAY'S LOW / HIGH ( )440.50 455.15
52 WK LOW / HIGH ( )299.3 470.9
NSE450.006.25 (+1.41 %)
PREV CLOSE( ) 443.75
OPEN PRICE ( ) 446.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 450.00 (1837)
VOLUME 2479566
TODAY'S LOW / HIGH( ) 440.55 455.30
52 WK LOW / HIGH ( )299.3 471
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-09 2005
Management Info
Malempati Venugopala Rao - Chairman - Managing Director
Registered Office

Address Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, Anakapalli,
Vishakhapatnam,
Andhra Pradesh-531021

Phone 0891 3061222 / 6601222

Email info@lauruslabs.com

Website www.lauruslabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

25Apr Appointment of Director
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Appointment of Chairman
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Resignation of Chairman
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Laurus Labs reports 30% fall in Q4 con
Laurus Labs has reported results for fourth quarter (Q4) and year ended..
25Apr Laurus Labs informs about press release
Laurus Labs has informed that it enclosed the Press Release on the finan..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1213.22237
Gross Profit 1643.1 3014.7
Operating Profit 29527973
Net Sales 14145.248123.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  7600.75 (5.52%)
M.Cap ( in Cr)9751.68
Procter&Gamble Healt (BSE)
peergroup  4916.35 (2.97%)
M.Cap ( in Cr)8160.84
Abbott India (BSE)
peergroup  26415.75 (0.53%)
M.Cap ( in Cr)56131.62
Pfizer (BSE)
peergroup  4253.30 (1.13%)
M.Cap ( in Cr)19457.88
Sanofi India (BSE)
peergroup  8324.10 (0.51%)
M.Cap ( in Cr)19170.92

Shareholding Pattern

MUTUAL FUNDS/UTI 6.68%
FI/BANKS/INSURANCE 4.75%
NON-INSTITUTION 35.07%
PROMOTERS 27.19%
GOVERNMENT 0%
FII 0%

About Laurus Labs Ltd.

Laurus Labs Ltd. was incorporated in the year 2005. Its today's share price is 450.25. Its current market capitalisation stands at Rs 24266.94 Cr. In the latest quarter, company has reported Gross Sales of Rs. 57734.5 Cr and Total Income of Rs.57894 Cr. The company's management includes Soumya Chava, Krishna Chaitanya Chava, Karnam Sekar, G Venkateswar Reddy, Lakshmana Rao CV, Venkata Ravi Kumar Vantaram, Ravindranath Kancherla, Rajesh Koshy Chandy, Aruna Bhinge, Satyanarayana Chava, Malempati Venugopala Rao.

It is listed on the BSE with a BSE Code of 540222 , NSE with an NSE Symbol of LAURUSLABS and ISIN of INE947Q01028. It's Registered office is at Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, AnakapalliVishakhapatnam-531021, Andhra Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.